Scarica l'app Stockscreener
10.76
7.72%
-0.90
Pre-mercato:
10.90
0.14
+1.30%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$11.66
Aprire:
$12.19
Volume 24 ore:
344.00K
Relative Volume:
0.12
Capitalizzazione di mercato:
$17.04M
Reddito:
$74,000
Utile/perdita netta:
$-13.43M
Rapporto P/E:
-1.1447
EPS:
-9.4
Flusso di cassa netto:
$-10.54M
1 W Prestazione:
-12.73%
1M Prestazione:
+3,056%
6M Prestazione:
+90.40%
1 anno Prestazione:
-59.24%
Intervallo 1D:
$10.05
$13.39
Intervallo di 1 settimana:
$7.5101
$18.00
Portata 52W:
$0.215
$39.84
Cyclacel Pharmaceuticals Inc Stock (CYCC) Company Profile
Nome
Cyclacel Pharmaceuticals Inc
Settore
Industria
Telefono
908-517-7330
Indirizzo
200 CONNELL DRIVE, BERKELEY HEIGHTS, NJ
Confronta CYCC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CYCC
Cyclacel Pharmaceuticals Inc
|
10.76 | 19.53M | 74,000 | -13.43M | -10.54M | -9.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Cyclacel Pharmaceuticals Inc Stock (CYCC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-07-18 | Ripresa | Oppenheimer | Outperform |
| 2020-04-27 | Ripresa | ROTH Capital | Buy |
| 2018-09-07 | Iniziato | Ladenburg Thalmann | Buy |
| 2015-10-16 | Iniziato | H.C. Wainwright | Buy |
| 2010-02-04 | Iniziato | Roth Capital | Buy |
| 2009-10-28 | Iniziato | Merriman | Buy |
| 2008-08-12 | Iniziato | Piper Jaffray | Buy |
| 2008-03-12 | Reiterato | Cantor Fitzgerald | Buy |
| 2008-03-12 | Reiterato | Collins Stewart | Buy |
| 2008-03-12 | Reiterato | Needham & Co | Buy |
| 2007-11-27 | Reiterato | Cantor Fitzgerald | Buy |
| 2007-08-10 | Reiterato | Cantor Fitzgerald | Buy |
| 2007-06-04 | Reiterato | Needham & Co | Buy |
| 2007-04-23 | Iniziato | Lazard Capital | Buy |
| 2007-04-10 | Iniziato | Cantor Fitzgerald | Buy |
Mostra tutto
Cyclacel Pharmaceuticals Inc Borsa (CYCC) Ultime notizie
(CYCCP) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Cyclacel Pharmaceuticals Inc. Stock Analysis and ForecastFree Wealth Planning Blueprint - jammulinksnews.com
What drives Cyclacel Pharmaceuticals Inc. stock priceDynamic portfolio growth - jammulinksnews.com
Is Cyclacel Pharmaceuticals Inc. a good long term investmentRemarkable growth - jammulinksnews.com
What analysts say about Cyclacel Pharmaceuticals Inc. stockExceptional financial outcomes - jammulinksnews.com
What makes Cyclacel Pharmaceuticals Inc. stock price move sharplyFree Stock Index Interpretation - Newser
CYCC’s Financial Health: Exploring Cyclacel Pharmaceuticals Inc’s Debt-to-Equity Ratio of 1.79 - investchronicle.com
Cyclacel Plunges 11.09% on Revenue Guidance Cut - AInvest
Wall Street Zen Downgrades Cyclacel Pharmaceuticals (NASDAQ:CYCC) to Sell - Defense World
CYCLACEL PHARMACEUTICALS INC 6% CNV PFD USD To Go Ex-Dividend On July 21st, 2025 With 0.15 USD Dividend Per Share - 富途牛牛
Big Moves And Bigger Questions For Biotech And Tech Stocks - Finimize
Cyclacel stock falls after paring 270% gain amid volatility concerns By Investing.com - Investing.com Canada
Cyclacel stock dips after trimming 270% surge amid volatility concerns - MSN
Cyclacel Shares Plunge 36% Amid Volatility, What's Driving the Sell-Off? - AInvest
Cyclacel stock falls after paring 270% gain amid volatility concerns - Investing.com Australia
Cyclacel Pharmaceuticals Addresses Recent Stock Price Volatility Amid Ongoing Business Developments - Quiver Quantitative
CYCLACEL PHARMACEUTICALS COMMENTS ON RECENT STOCK PRICE VOLATILITY - Yahoo Finance
Cyclacel Pharmaceuticals Stock Plunges 37.23% - AInvest
Cyclacel Pharmaceuticals Stock Surges Amid Positive Research Findings - AInvest
Why Cyclacel Pharmaceuticals Inc. stock attracts strong analyst attentionExpert Backed Predictions - Newser
Why Is Cyclacel Pharmaceuticals Stock Soaring On Tuesday? - Benzinga
Cyclacel's Volatile Surge: Can This Biotech Stock Defy Gravity? - AInvest
Cyclacel Pharmaceuticals Stock Soars: Investing or Waiting? - timothysykes.com
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Upgraded by Wall Street Zen to “Hold” Rating - Defense World
Fitters: US$1m cash added to Cyclacel deal to address stock volatility since signing - The Malaysian Reserve
Cyclacel Stock Surges 50% After Amending Exchange Agreement with FITTERS - MSN
Cyclacel stock soars after amendment to exchange agreement with FITTERS By Investing.com - Investing.com Nigeria
Cyclacel stock soars after amendment to exchange agreement with FITTERS - Investing.com Australia
Cyclacel sweetens Fitters acquisition deal with US$1m cash addition - The Malaysian Reserve
Cyclacel Pharmaceuticals Amends Exchange Agreement with FITTERS - TipRanks
CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER - The Manila Times
Breakthrough: New Drug Shows Effectiveness Against Untreatable Youth Liver Cancer, Research Reveals - Stock Titan
Cyclacel Pharmaceuticals adjusts shareholder rights, amends stock - MSN
Cyclacel Pharmaceuticals Inc Azioni (CYCC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):